This company listing is no longer active
AstraZeneca (AZNA) Stock Overview
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
AZNA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
AstraZeneca PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£78.50 |
| 52 Week High | UK£83.00 |
| 52 Week Low | UK£56.00 |
| Beta | 0.19 |
| 1 Month Change | -3.68% |
| 3 Month Change | 7.53% |
| 1 Year Change | 11.35% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 36.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| AZNA | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | 0.6% | 2.9% | -1.4% |
| 1Y | 11.3% | 16.4% | 34.8% |
Return vs Industry: AZNA exceeded the Austrian Pharmaceuticals industry which returned 1.7% over the past year.
Return vs Market: AZNA underperformed the Austrian Market which returned 40.7% over the past year.
Price Volatility
| AZNA volatility | |
|---|---|
| AZNA Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in AT Market | 7.1% |
| 10% least volatile stocks in AT Market | 2.6% |
Stable Share Price: AZNA has not had significant price volatility in the past 3 months compared to the Austrian market.
Volatility Over Time: AZNA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 94,300 | Pascal Claude Soriot | www.astrazeneca.com |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya.
AstraZeneca PLC Fundamentals Summary
| AZNA fundamental statistics | |
|---|---|
| Market cap | €247.22b |
| Earnings (TTM) | €7.97b |
| Revenue (TTM) | €49.31b |
Is AZNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZNA income statement (TTM) | |
|---|---|
| Revenue | US$58.13b |
| Cost of Revenue | US$9.73b |
| Gross Profit | US$48.40b |
| Other Expenses | US$39.00b |
| Earnings | US$9.40b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 10, 2026
| Earnings per share (EPS) | 6.06 |
| Gross Margin | 83.26% |
| Net Profit Margin | 16.17% |
| Debt/Equity Ratio | 67.2% |
How did AZNA perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/05 23:20 |
| End of Day Share Price | 2026/01/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AstraZeneca PLC is covered by 56 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |